EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

Michael Szarek, Deepak L Bhatt, Michael Miller, Eliot A Brinton, Terry A Jacobson, Jean-Claude Tardif, Christie M Ballantyne, R Preston Mason, Steven B Ketchum, Armando Lira Pineda, Ralph T Doyle, Ph Gabriel Steg und 1 weitere

Journal of the American College of Cardiology · 2024

DOI: 10.1016/j.jacc.2024.02.016 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024. Verfasst von Michael Szarek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; CPC Clinical Research, Aurora, Colorado, USA; State Univers…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Hypertriglyceridemia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elevated lipoprotein(a) (Lp[a]) concentrations are associated with increased cardiovascular event risk even in the presence of well-controlled low-density lipoprotein cholesterol levels, but few treatments are documented to reduce this residual risk. OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was to explore the cardiovascular benefit of icosapent ethyl (IPE) across a range of Lp(a) levels. METHODS: A total of 8,179 participants receiving statin therapy with established cardiovascular disease or age ≥50 years with diabetes and ≥1 additional risk factor, fasting triglyceride 1.69 to 5.63 mmol/L, and low-density lipoprotein cholesterol 1.06 to 2.59 mmol/L were randomized to receive 2 g twice daily of IPE or matching placebo. Relationships between continuous baseline Lp(a) mass concentration and risk for first and total (first and subsequent) major adverse cardiovascular events (MACE) were analyzed, along with the effects of IPE on first MACE among those with Lp(a) concentrations ≥50 or 0.10). IPE significantly reduced first MACE in subgroups with concentrations ≥50 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesHypertriglyceridemiaHumansMiddle AgedRisk FactorsLipoprotein(a)TriglyceridesCholesterol, LDLHeart Disease Risk FactorsEicosapentaenoic Acid

Stichwörter der Autor:innen

Lp(a)icosapent ethyltriglycerides

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)eicosapentaenoic acid ethyl esterTriglyceridesCholesterol, LDLEicosapentaenoic Acid

Autor:innen und Institutionen

  • Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; CPC Clinical Research, Aurora, Colorado, USA; State University of New York, Downstate Health Sciences University, Brooklyn, New Y…
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
  • Utah Lipid Center, Salt Lake City, Utah, USA.
  • Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Zitieren

APA

Szarek, M., Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Mason, R. P., Ketchum, S. B., Lira Pineda, A., Doyle, R. T., Steg, P. G., & REDUCE-IT Investigators (2024). Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.02.016

Vancouver

Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Tardif JC, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.02.016

BibTeX
@article{Szarek2024,
  author = {Szarek, Michael and Bhatt, Deepak L and Miller, Michael and Brinton, Eliot A and Jacobson, Terry A and Tardif, Jean-Claude and Ballantyne, Christie M and Mason, R Preston and Ketchum, Steven B and Lira Pineda, Armando and Doyle, Ralph T and Steg, Ph Gabriel and REDUCE-IT Investigators, REDUCE-IT Investigators},
  title = {Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl},
  journal = {Journal of the American College of Cardiology},
  year = {2024},
  doi = {10.1016/j.jacc.2024.02.016}
}
Kostenlos starten →